China Biotech Services Holdings
China Biotech Services Holdings Limited, commonly referred to as CBSH, is a prominent player in the biotechnology sector, headquartered in China (CN). Established in 2001, the company has made significant strides in providing comprehensive services across the biopharmaceutical and healthcare industries, focusing on drug development, clinical trials, and regulatory compliance. With a strong operational presence in major regions of China, CBSH offers a unique suite of services that includes laboratory testing, data management, and consulting. Their commitment to innovation and quality has positioned them as a trusted partner for pharmaceutical companies seeking to navigate the complexities of the biotech landscape. Notable achievements include successful collaborations with leading global firms, underscoring their market position as a key service provider in the rapidly evolving biotech industry.
DitchCarbon Score
How does China Biotech Services Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China Biotech Services Holdings's score of 21 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
China Biotech Services Holdings's reported carbon emissions
In 2022, China Biotech Services Holdings reported total carbon emissions of approximately 11,273,000 kg CO2e. The breakdown of these emissions includes about 2,200 kg CO2e from Scope 1, approximately 11,237,000 kg CO2e from Scope 2, and around 33,700 kg CO2e from Scope 3 emissions. Notably, the majority of their emissions stem from electricity consumption, which is reflected in the high Scope 2 figures. Over the years, the company has shown a trend of fluctuating emissions. In 2021, total emissions were about 238,000 kg CO2e, with Scope 1 contributing approximately 38,000 kg CO2e and Scope 2 accounting for about 159,000 kg CO2e. This indicates a significant increase in emissions in 2022 compared to the previous year. Despite the increase in emissions, there are currently no publicly disclosed reduction targets or climate pledges from China Biotech Services Holdings. The absence of specific initiatives or commitments suggests that the company may need to enhance its climate strategy to align with industry standards and expectations for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 30,000 | 00,000 | 00,000 | 0,000 |
| Scope 2 | 467,000 | 000,000 | 000,000 | 00,000,000 |
| Scope 3 | 43,700 | 00,000 | 00,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
China Biotech Services Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
